Please login to the form below

Not currently logged in
Email:
Password:

Nektar Therapeutics

This page shows the latest Nektar Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Merck to acquire Pandion Therapeutics for $1.85bn

Merck to acquire Pandion Therapeutics for $1.85bn

Merck (MSD) has signed a deal to acquire Pandion Therapeutics for approximately $1.85bn, gaining access to a pipeline of immune modulators for the treatment of autoimmune diseases. ... A number of other pharma companies are also developing IL-2 therapies,

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Nektar Therapeutics’ CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II ... 639. Cynapsus Therapeutics / Sunovion. Acquisition corporate.

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery). ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Christian Pangratz to head up Sterna Biologicals Christian Pangratz to head up Sterna Biologicals

    He has also held roles for Nektar Therapeutics, Bayer and Pfizer.

  • Nektar Therapeutics appoints Jeff Ajer Nektar Therapeutics appoints Jeff Ajer

    He joins as an independent director. California, US-based Nektar Therapeutics has appointed Jeff Ajer as its independent director to the company’s board of directors, following his 25 years’ of ... Howard Robin, president and CEO, Nektar Therapeutics,

  • Cubist’s Dr Lorianne Masuoka jumps ship to InVivo Cubist’s Dr Lorianne Masuoka jumps ship to InVivo

    Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... Prior to her time at Cubist, she served in various roles of

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...